|
|
Blood, 1 July 2004, Vol. 104, No. 1, pp. 159-165.
Prepublished online as a Blood First Edition Paper on March 16, 2004; DOI 10.1182/blood-2003-11-4077.
Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Bleeding risks associated with inheritance of the Quebec platelet disorder
Heather McKay,
Francine Derome,
M. Anwar Haq,
Susan Whittaker,
Emmy Arnold,
Frédéric Adam,
Nancy M. Heddle,
Georges E. Rivard, and
Catherine P. M. Hayward
From the Department of Pathology and Molecular Medicine and the Department of Medicine, McMaster University, Hamilton, ON, Canada; and the Department of Hematology and Oncology, Hôpital Sainte Justine, Montreal, QC, Canada.
Quebec platelet disorder (QPD) is an autosomal dominant bleeding disorder associated with increased urokinase-type plasminogen activator in platelets and -granule protein degradation. To determine bleeding risks and common manifestations of QPD, a history questionnaire was developed and administered to 127 relatives in a family with QPD. Data entry was done blinded to affected and unaffected status, determined by assays for platelet urokinase-type plasminogen activator (u-PA) and fibrinogen degradation. Odds ratios (ORs), with 95% confidence intervals (CIs), were determined for items queried. Summative bleeding scores for each individual were calculated using items with OR more than 1. Mean ages (34 years; range, 1-89 years) were similar for affected (n = 23) and unaffected (n = 104) family members. Affected individuals had higher mean bleeding scores (P < .0001) and a much higher likelihood (OR > 20) of having bleeding that led to lifestyle changes, bruises that spread lower or as large or larger than an orange or both, joint bleeds, bleeding longer than 24 hours after dental extractions or deep cuts, and received or been recommended other treatments (fibrinolytic inhibitors) for bleeding. Individuals with QPD and exposure(s) to hemostatic challenges had experienced excessive bleeding only when fibrinolytic inhibitors had not been used. These data illustrate that QPD is associated with increased risks of bleeding that can be modified by fibrinolytic inhibitors.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Quebec platelet syndrome: from the bench to the family
- James N. George
Blood 2004 104: 8.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
M. Diamandis, A. D. Paterson, J. M. Rommens, D. K. Veljkovic, J. Blavignac, D. E. Bulman, J. S. Waye, F. Derome, G. E. Rivard, and C. P. M. Hayward
Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes
Blood,
February 12, 2009;
113(7):
1543 - 1546.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. K. Veljkovic, G. E. Rivard, M. Diamandis, J. Blavignac, E. M. Cramer-Borde, and C. P. M. Hayward
Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation
Blood,
February 12, 2009;
113(7):
1535 - 1542.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. P. M. Hayward
Diagnosis and Management of Mild Bleeding Disorders
Hematology,
January 1, 2005;
2005(1):
423 - 428.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|